Sex differences shaped COVID-19 severity in an Italian district registry

A local register-based study from the Apulian District of Foggia adds another clear clinical signal to the pandemic record: men with COVID-19 were more likely to be hospitalized and to die, while women were more likely to achieve viral clearance. The analysis covered confirmed cases from 29 February to 30 June 2020 and drew on surveillance data from the regional GIAVA-COVID registry. In a setting where testing, admission decisions, and follow-up were being made under intense pressure, the sex-based separation in outcomes remained visible across several clinically relevant endpoints.

The cohort included 1175 confirmed cases, and women made up 50.7% of the total. Median age was 55 years. Among 55,131 tests performed, the investigators were able to compare hospitalization, viral clearance, and fatality across sexes, and the differences were not subtle. Men had a higher proportion of hospitalization with COVID-19 diagnosis, 45.4% versus 37.9% in women. Women, however, stayed in hospital longer on average, with a mean length of stay of 31.3 ± 14.6 days compared with 26.8 ± 14.4 days in men.

The pattern did not end at admission. Women achieved virus clearance more often than men, 84.2% versus 79.3%, and the time to clearance was measured at 28.0 ± 12.1 days in women and 29.4 ± 12.9 days in men. Men also had a higher case fatality rate, 16.1% versus 10.4% in women. The mean time from diagnosis to death was shorter in men, 10.6 ± 10.7 days, than in women, 14.5 ± 14.4 days. In practical terms, the male trajectory in this cohort moved faster toward deterioration and death, while women were more likely to survive long enough to experience a longer in-hospital course.

Hospitalization, clearance, and death did not move in the same direction

The separation across endpoints points to different layers of disease biology rather than a single mechanism. COVID-19 is not one uniform process; it combines viral replication, host immune activation, endothelial injury, and downstream organ dysfunction. A higher hospitalization rate in men suggests greater early clinical severity or a lower threshold for progression to pneumonia or systemic illness. Faster death after diagnosis in men fits with more abrupt inflammatory decompensation, a pattern seen in many observational datasets across the pandemic.

Longer hospital stays in women do not imply worse survival. In this cohort, women more often cleared the virus and lived longer after diagnosis, which naturally creates more time for inpatient management, rehabilitation, oxygen support, or prolonged isolation before discharge. A shorter stay in men can reflect earlier death rather than easier recovery, and the mortality data make that interpretation hard to avoid. The endpoint mix matters because hospitalization duration alone can mislead if it is read without the fatality context.

Age and comorbidity sharpened the sex gradient

Male sex was not the only factor associated with a worse course. Age 55 years or older and the presence of at least one underlying comorbidity significantly increased the risk of hospitalization, persistent infection, and death. The clinical signal is consistent with the broader understanding of COVID-19 risk: older age and chronic disease increase vulnerability to hypoxemia, dysregulated inflammation, and impaired physiologic reserve. In that context, sex appears to function as an additional modifier of risk rather than a standalone explanation.

The age threshold is clinically relevant because the median age of the entire cohort was 55 years, placing many patients near the point where risk begins to rise more steeply. Comorbidity likely amplifies that vulnerability through overlapping mechanisms such as vascular dysfunction, metabolic stress, and reduced immune resilience. In real-world care, those factors do not operate in isolation. A male patient over 55 with chronic disease starts from a biologically disadvantaged position when infected with SARS-CoV-2, and this registry shows that disadvantage translating into measurable outcomes.

What the Foggia registry adds to bedside practice

This was a retrospective epidemiological study, so it cannot prove causation. It can, however, document a clinically important pattern in a defined population using local surveillance data collected during the first months of the pandemic. The value of the analysis lies in its practical message: sex is not a cosmetic demographic field in a chart. It may alter how clinicians interpret risk, watch for deterioration, and counsel patients about prognosis.

By treating sex as a variable with potential prognostic weight, clinicians can better match monitoring intensity to the patient in front of them. Men with COVID-19 in this dataset were more likely to require hospitalization and more likely to die, while women showed higher rates of viral clearance. Those differences suggest that sex-disaggregated reporting should remain routine in infectious disease surveillance and in hospital audit systems, especially when policy decisions depend on aggregate averages that may hide important clinical asymmetry.

Limits of a local registry, and why the signal still matters

The study reflects one district in Italy during a specific period of the pandemic, so the findings should not be treated as universal for every setting or every viral wave. Testing strategies, admission thresholds, treatment availability, and public health pressure changed rapidly during 2020. Those conditions can shape observed outcomes even when registry data are robust. Still, the direction of effect across multiple endpoints gives the result internal consistency: men fared worse on hospitalization and death, women fared better on clearance, and age plus comorbidity worsened the course for both sexes.

For clinicians, the most concrete lesson is that sex should be read alongside age and comorbidity when COVID-19 risk is discussed or triaged. For public health teams, the data support routine sex-stratified surveillance rather than pooled averages. For researchers, the study reinforces a long-standing question in infectious disease biology: why the host response diverges so consistently between men and women, even when the pathogen is the same.


Reporting by Dr. A.R. Athira, MBBS for Medicine World Foundation, with additional data provided by BMJ Open.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA